


DARWIN EU® study

# Treatment patterns and user characteristics for novel migraine medicines



## Why is this study needed?

Novel medicines called CGRP antagonists are used to treat migraine in adults who have at least 4 migraine days per month. Recently, safety signals have emerged on a potential association between the use of these medicines and insomnia, erectile dysfunction and increased blood pressure.



## How were the results used?

The study helped PRAC to reach a conclusion on these 3 safety signals by providing insight into how often these events occur in migraine patients in general.

The conclusion was that no further action was needed.



## How was this conducted?

PRAC requested this [study](#) to look at patients with migraine treated with CGRP antagonists. The study aimed to understand who is using the medicines, for how long and how often they experience insomnia, erectile dysfunction and increased blood pressure regardless of treatment. The study used health data from databases in 4 EU countries.



## Why do these results matter?

The study helped assess three safety signals and ease safety concerns.

### More information



<https://catalogues.ema.europa.eu/>

© European Medicines Agency, 2026

Reproduction is authorised provided the source is acknowledged. For any use or reproduction of images or other materials that are not under the copyright of the European Medicines Agency as specified subsequently, permission must be sought directly from the respective copyright holders. The indicated images or other materials are copyright protected and have been licensed by the European Medicines Agency via Adobe Stock, Dreamstime or iStockphoto, as shown respectively in the credit lines of each image or other material.



[www.ema.europa.eu](http://www.ema.europa.eu)

An agency of the European Union

